Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely aligns with the FDA-prescribed labeling for indications, dosing (where provided), contraindications, warnings, adverse reactions, and patient guidance. Notable discrepancies include incorrect initial genital herpes dosing, incorrect recurrent genital herpes dosing, and an MOA statement not clearly supported by the provided label. Overall, the alignment is good with a few dosing inaccuracies and an omission.
Category Scores
Accurate Statements
Acyclovir is indicated for the acute treatment of herpes zoster (shingles).
INDICATIONS AND USAGE; DOSAGE AND ADMINISTRATION (Acute treatment of herpes zoster)
Acyclovir is indicated for the treatment of initial and recurrent genital herpes.
INDICATIONS AND USAGE; DOSAGE AND ADMINISTRATION (Genital Herpes)
Acyclovir is indicated for the treatment of varicella (chickenpox).
INDICATIONS AND USAGE; DOSAGE AND ADMINISTRATION (Treatment of Chickenpox)
IV acyclovir dosing of 10 mg/kg IV every 8 hours, adjusted for kidney function.
DOSAGE AND ADMINISTRATION (IV dosing for severe HSV/VZV infections)
Oral dosing for shingles (herpes zoster): 800 mg PO five times daily for 7–10 days.
DOSAGE AND ADMINISTRATION (Acute treatment of herpes zoster)
Topical 5% acyclovir cream/ointment is used for cold sores with limited systemic exposure.
DOSAGE AND ADMINISTRATION (Topical 5% cream/ointment for cold sores)
Common adverse events include nausea, diarrhea, headache, and vomiting.
ADVERSE REACTIONS
IV use can involve nephrotoxicity risk if not hydrated and can cause phlebitis at the injection site.
WARNINGS
Rare but serious: allergic reactions, confusion or seizures (more likely in elderly or with kidney problems).
ADVERSE REACTIONS
Dose adjustment is required in renal impairment.
DOSAGE AND ADMINISTRATION; Table 3. Dosage Modification for Renal Impairment
IV acyclovir requires adequate hydration to reduce kidney risk.
WARNINGS
Other nephrotoxic drugs (e.g., NSAIDs, certain antibiotics) can increase risk of kidney injury.
WARNINGS
Pregnancy and breastfeeding: acyclovir is generally considered compatible if benefits outweigh risks; use as prescribed by your clinician.
Pregnancy: Teratogenic Effects; Information for Patients
Known allergy to acyclovir or valacyclovir: should not take or use it.
CONTRAINDICATIONS
Significant kidney disease without doctor’s guidance: use with caution.
DOSAGE AND ADMINISTRATION; WARNINGS
Take oral doses with plenty of water; stay well hydrated.
Information for Patients
Finish the full course even if symptoms improve.
Information for Patients
Topical product is mainly for cold sores, not for treating full-blown systemic infections.
DOSAGE AND ADMINISTRATION
Always follow your healthcare provider’s exact dosing and duration.
DOSAGE AND ADMINISTRATION
Unsupported Statements
It is a nucleoside analog; once activated inside infected cells, it inhibits viral DNA polymerase and stops viral DNA replication.
The provided label does not describe mechanism of action in the Clinical Pharmacology section as shown.
Contradictions
Low
AI Statement
Oral dosing for genital herpes (initial episode): around 400 mg PO five times daily for about 7–10 days.
Label Reference
DOSAGE AND ADMINISTRATION (Genital Herpes)
Low
AI Statement
Oral dosing for genital herpes (recurrent): around 400 mg PO five times daily for about 5 days.
Label Reference
DOSAGE AND ADMINISTRATION (Intermittent Therapy)
Low
AI Statement
Oral dosing for chickenpox (varicella) in children and adults: around 800 mg PO five times daily for about 5 days.
Label Reference
DOSAGE AND ADMINISTRATION (Treatment of Chickenpox)
Important Omissions
Mechanism of action (MOA) not clearly documented in the provided label excerpt; stated MOA claim is not substantiated by the label content shown.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-aligned safety information is largely captured; minor dosing discrepancies are identified as contradictions rather than safety risks.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Dosing inaccuracies for genital herpes (initial and recurrent) and varicella pediatric dosing; MOA not clearly evidenced in label excerpt.
Suggested Improvement
Correct initial genital herpes dosing to 200 mg every 4 hours (5 times daily) for 10 days; recurrent therapy to 200 mg every 4 hours (5 times daily) for 5 days; ensure pediatric varicella dosing reflects weight-based guidelines; explicitly include mechanism of action if applicable in the label excerpt.